Viridian Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on January 10, 2025, covering events occurring on January 7, 2025. The Company is a biotechnology firm incorporated in Delaware, with its principal executive offices in Waltham, MA. Its common stock trades on The Nasdaq Stock Market under the symbol "VRDN."
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointments.
Material Changes
The primary material change reported is the appointment of Seth Harmon as Chief Financial Officer (CFO), effective January 1, 2025. Mr. Harmon previously served as the Company's Senior Vice President of Finance and Accounting and Principal Financial Officer. His appointment includes the following compensation adjustments:
- Base Salary: Increased to $480,000.
- Target Discretionary Bonus: Remains at 40% of base salary.
- Stock Option Award: Grant date value of $1,662,000.
- Restricted Stock Unit (RSU) Award: Grant date value of $554,000.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that an updated employment agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2024. No unusual items or related party transactions were disclosed.
Key Facts for Investor Verification
- Verify the effective date of Seth Harmon's CFO appointment (January 1, 2025).
- Confirm the total grant date value of equity awards ($2,216,000 combined).
- Review the upcoming Form 10-K for the full text of the updated employment agreement.
- Note that the filing does not contain updated financial performance data.